[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intestinal-flora\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intestinal-flora":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,75,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100642940","phase-1-research-on-the-efficacy-and-mechanism-of-shouhui-tongbian-capsules-in-treating-postoperative-constipation-of-benign-anal-and-rectal-diseases-based-on-gut-microbiota-analysis-100642940",false,"NCT07648394","Research on the Efficacy and Mechanism of Shouhui Tongbian Capsules in Treating Postoperative Constipation of Benign Anal and Rectal Diseases Based on Gut Microbiota Analysis","Inclusion Criteria: Age between 18 and 75 years old, male or female. Undergoing surgery for benign anorectal diseases (e.g., mixed hemorrhoids, anal fistula, anal fissure).\n\nMeeting the diagnostic criteria for postoperative constipation (e.g., fewer than 3 spontaneous bowel movements per week, or difficulty in defecation).\n\nAble to understand the study procedures and voluntarily sign the informed consent form.\n\nAble to cooperate with medication administration, follow-up visits, and data collection.\n\nExclusion Criteria:Severe organic diseases of the heart, liver, kidney, or other vital organs.\n\nHistory of inflammatory bowel disease, irritable bowel syndrome, or severe chronic constipation unrelated to surgery.\n\nHistory of gastrointestinal surgery (other than the planned anorectal surgery) within the past 3 months.\n\nPregnancy, breastfeeding, or planned pregnancy during the study period (for female participants).\n\nKnown allergy or contraindication to the study drugs (Shouhui Tongbian Capsules or lactulose).\n\nCurrent use of other laxatives, prokinetic drugs, or traditional Chinese medicine for constipation within 1 month before enrollment.\n\nSevere mental disorders, cognitive impairment, or inability to communicate effectively.\n\nParticipation in other clinical trials within the past 3 months. Any other condition judged by the investigator to make the participant unsuitable for this study.","ALL","18 Years","75 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Study Title A study to learn how Shouhui Tongbian Capsules works to relieve constipation after anorectal surgery, and explore its effects linked to gut bacteria.\n\nWhy we do this study Constipation is a common problem after surgery for hemorrhoids, anal fistula and other benign anorectal diseases. It causes pain, slows wound healing and lowers quality of life. Traditional laxatives may lead to stomach pain, electrolyte problems and drug dependence.\n\nShouhui Tongbian Capsules is a traditional Chinese herbal medicine. It can ease constipation and protect the intestinal tract at the same time. This research aims to check how well this medicine works for post-surgery constipation, whether it reduces pain, and find out its working mechanism related to gut microbiota. We also want to collect evidence for better combined traditional Chinese and Western medicine treatment in clinic.\n\nWho can take part Adults aged 18 to 75 who receive surgery for benign anorectal diseases and have constipation Fully aware of the study and willing to sign an informed consent form People with severe organ diseases, mental illness, cancer, bleeding disorders, pregnancy or other conditions will not be included.\n\nHow the study works\n\nThis is a prospective, randomized, controlled clinical trial. A total of 120 patients will be randomly divided into two groups (60 people each):\n\nTest group: Take Shouhui Tongbian Capsules, 2 pills three times a day for 8 weeks.\n\nControl group: Take lactulose oral solution, the common medicine for constipation.\n\nWe will assess symptoms regularly before, during and after treatment. We will record constipation severity, traditional Chinese medicine symptom scores, pain scores (VAS), quality of life (SF-36), physical signs and blood test results. We will also test gut bacteria and inflammation levels to analyze the medicine's mechanism.\n\nSafety All participants will be closely monitored throughout the study. We will record any discomfort or side effects in a timely manner to ensure safety.\n\nExpected benefits This study will confirm the effectiveness and safety of Shouhui Tongbian Capsules for post-anorectal surgery constipation. It may help relieve your constipation and post-operative pain, speed up recovery and improve daily life. The results will also help doctors choose better treatments for similar patients in the future.\n\nStudy timeline May - June 2026: Complete ethical review and study preparation July - September 2026: Recruit participants and start treatment Late 2026 - Early 2027: Finish data collection, analysis and paper writing",[27,28,29,30],"Intestinal Flora","Anorectal Diseases","Surgery","Constipation","NOT_YET_RECRUITING","2026-06-10",{"date":34,"type":35},"2026-06-15","ACTUAL",{"date":37,"type":20},"2026-08-01",{"date":39,"type":20},"2027-06-30",{"name":41,"class":42},"China-Japan Friendship Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100639308","repeated-transcranial-magnetic-stimulation-for-the-treatment-of-diarrhea-predominant-irritable-bowel-syndrome-a-randomized-clinical-trial-100639308","NCT07581756","Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial","Repeated Transcranial Magnetic Stimulation (rTMS) for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial","rTMS","Inclusion Criteria:\n\nEligible participants had to be between 18- 60 years of age and fulfill the Rome IV criteria for IBS-D. Specifically, patients must have experienced recurrent abdominal pain at least one day per week in the last three months, with symptom onset at least six months prior to diagnosis, associated with defecation or a change in the frequency or form (appearance) of stool. More than 25% of stool episodes be classified as Bristol Stool Form Scale (BSFS) type 6 or 7, and fewer than 25% as type 1 or 2. In addition, patients were required to exhibit moderate to severe symptoms, defined as an Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) score greater than 175 (on a 500-point scale). Dietary preferences of all participants included non vegetarian options and participants maintain stable dietary habits for at least one month prior to randomization. Moreover, patients aged over 50 were required to provide documentation of a normal colonoscopy performed within the preceding three years.\n\nExclusion Criteria:\n\nThe exclusion criteria included a completion rate of daily diaries of less than 50% during the screening period, a history of organic gastrointestinal disease, such as inflammatory bowel disease, a history of surgical resection of the GI tract or cholecystectomy, a recent diagnosis of Helicobacter pylori infection within the past 2 years, a history of gluten or lactose intolerance, a history of malignancy, or a history of neurological or psychiatric conditions. Additionally, individuals with severe systemic diseases, including uncontrolled diabetes mellitus, hyperthyroidism, or severe hepatic, renal, or cardiac insufficiency, were excluded. The use of probiotic or prebiotic supplements, antibiotics (including rifaximin), prokinetic or antidiarrheal agents, tricyclic antidepressants, or immunosuppressive therapies was not permitted within 4 wk prior to screening. Prohibited conditions during the study period included pregnancy, lactation, or being within 12 months postpartum. Lastly, participants with severe needle phobia, metal allergies, implanted cardiac pacemakers, or a known allergic diathesis were excluded. All participants provided their voluntary, written, informed consent prior to their inclusion.","70 Years",{"count":54,"type":20},46,[56],"NA","Objectives: This study aims to evaluate the clinical efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore the potential underlying mechanisms by which rTMS alleviates clinical symptoms in IBS-D patients.\n\nDesign: This is a clinical trial that uses clinical symptom scales to assess the therapeutic effect of rTMS on IBS-D patients. Meanwhile, gut microbiota and metabolite profiling, as well as the methane-hydrogen breath test, will be applied to investigate the mechanism of action from the perspectives of gut microecology, intestinal motility, and metabolism, so as to provide scientific evidence for the clinical application of rTMS in the treatment of IBS-D.",[59,60,61,62,27],"Irritable Bowel Syndrome","Irritable Bowel Syndrome With Diarrhea (IBS-D)","Repetitive Transcranial Magnetic Stimulation (rTMS)","Chronic Diarrhea",[64,61],"Irritable Bowel Syndrome with diarrhea (IBS-D)","RECRUITING","2026-05-06",{"date":68,"type":35},"2026-05-12",{"date":70,"type":35},"2024-12-01",{"date":72,"type":20},"2026-07-01",{"name":74,"class":42},"The First Affiliated Hospital of Soochow University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":15,"minAge":16,"maxAge":52,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":95,"locationsCount":43},"100589896","phase-1-efficacy-of-repeated-transcranial-magnetic-stimulation-combined-with-a-live-probiotic-tablet-combined-bifidobacterium-lactobacillus-enterococcus-and-bacillus-cereus-tablets-live-in-diarrhea-predominant-irritable-bowel-syndrome-ibs-d-100589896","NCT06960369","Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)","Inclusion Criteria:\n\n1. Must meet the diagnostic criteria for Irritable Bowel Syndrome of Rome IV.\n2. Age range between 18-70 years.\n3. The duration of the disease is more than 6 months.\n4. There are no pathologic abnormalities or biochemical changes that could explain the bowel-related symptoms.\n5. The IBS symptom severity score at baseline must not be less than 75.\n6. No pharmacological treatment (excluding emergency treatment) for IBS for at least 2 weeks prior to the start of treatment; no concurrent participation in other clinical programs.\n7. Voluntarily sign the relevant informed consent form and voluntarily participate in this clinical project.\n\nExclusion Criteria:\n\n1. Be less than 18 years old or more than 70 years old.\n2. Those who suffer from severe liver, kidney, hematopoietic system diseases, cardiovascular and cerebrovascular diseases, and psychiatric diseases that significantly affect cognitive function.\n3. Patients with clear organic diseases of the intestinal tract; patients with diabetes, hyperthyroidism and other systemic diseases that affect the digestive tract dynamics; patients who have had a history of surgery on the anus and intestines or the abdomen.\n4. The presence of the following conditions affecting the efficacy or safety judgment: ① regular use of preparations and drugs affecting gastrointestinal dynamics or function; ② treatment with other treatments and drugs that may affect the results of the judgment.\n5. Those who are pregnant, breastfeeding or less than 12 months after delivery.\n6. Patients with severe fear of needles, metal allergies or sensitivities, or those with pacemakers.\n7. Patients who do not comply with the randomized assignment to the treatment group or have a tendency to be unstable such as poor compliance.\n8. Patients who are participating in other research projects.\n9. Those who do not want to sign the informed consent form.",true,{"count":83,"type":20},400,[23],"To evaluate the overall efficacy of repeated Transcranial Magnetic Stimulation(rTMS) combined with a Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)\n\nMethods:\n\nClinical efficacy evaluation of TMS combined with Live Probiotic tablet for chronic diarrhea in IBS patients. The 400 IBS patients who meet the recruitment criteria for the clinical study will be randomized into 100 patients in rTMS combined with Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live), rTMS combined placebo, shamrTMS combined with Live Probiotic tablet(Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) and shamrTMS combined placebo group. Corresponding treatment was given for 2 week, rTMS group received 1 Hz\u002Fs, 20 min for 2 week; Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week, shamrTMS group received 0 Hz\u002Fs, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week. Clinical assessment included symptoms, stool traits, mood, and sleep.\n\n2\\. Study on the mechanism of using intestinal flora data to evaluate the treatment of chronic diarrhea in IBS patients. 30 cases each were included in the 4 groups of IBS-eligible patients, and repeated transcranial magnetic stimulation treatment was given to the patient group for 2 week, and the patient group underwent the assessment of investigating the quantity and metabolic changes of the intestinal flora in feces before and after the treatment.",[59,60,61,87,62,27],"Probiotic",[64,61,87],"2025-05-05",{"date":91,"type":35},"2025-05-07",{"date":70,"type":35},{"date":94,"type":20},"2026-06-01",{"name":74,"class":42},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":81,"sex":15,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":116,"leadSponsor":118,"locationsCount":43},"100569157","characteristics-and-clinical-significance-of-gut-microbiota-in-patients-with-monoclonal-gammopathy-100569157","NCT06690593","Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy","Gut Microbiota Profiling in Patients With Monoclonal Gammopathy: Implications for Disease Pathogenesis and Progression","(I) Inclusion Criteria:\n\n1. Age 45 years or older;\n2. Negative screening for monoclonal protein by MALDI-TOF MS;\n3. No significant diseases found upon medical examination, and confirmed not to have any diseases related to this study;\n4. Sufficient whole blood, plasma, serum, and stool samples available, and relevant case data can be provided.\n\n(II) Exclusion Criteria:\n\n1. History of intestinal tumors, irritable bowel syndrome, or inflammatory bowel disease, or diagnosed during hospitalization;\n2. Antibiotic treatment received in the past month; Presence of severe systemic diseases, including malignant tumors;\n3. Insufficient sample volume, or presence of severe hemolysis, lipemia, jaundice, or other unqualified sample conditions.","45 Years",{"count":105,"type":20},2990,"OBSERVATIONAL","This is an observational case-control study, aiming to systematically analyze the gut microbiome characteristics of patients with monoclonal gammopathy of undetermined significance (MGUS). The study will collect blood and stool samples from MGUS patients, non-MGUS patients (with similar diseases), and healthy controls, and perform multi-omics detection including microbiomics, peptidomics, and biochemical immunology. It will comprehensively analyze the abnormal features of the gut microbiome in MGUS patients, which may help provide new biomarkers and potential mechanisms for the diagnosis, prognosis evaluation, and treatment strategies of MGUS.",[109,27,110,111],"Monoclonal Gammopathy of Undetermined Significance (MGUS)","Multiple Myeloma","M-Protein","2024-12-26",{"date":114,"type":35},"2024-12-27",{"date":112,"type":20},{"date":117,"type":20},"2026-12-30",{"name":119,"class":42},"Zhujiang Hospital"]